Changes in hormone-receptor status in luminal breast cancers between primary tumour and metastases: Results of the observational cohort GIM-13 AMBRA study
ME Cazzaniga(Casa Sollievo della Sofferenza), Giorgio Mustacchi(University of Trieste), Michela Donadio(Azienda Ospedaliero Universitaria San Giovanni Battista), Clara Natoli(Kliniken Essen-Mitte), Filippo Montemurro(Roche (Switzerland)), Monica Giordano(Ospedale Sant'Anna), Antônio Bernardo(Fondazione Salvatore Maugeri), P. Pronzato(Accademia Nazionale dei Lincei), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Lorenzo Livi(European Society for Sexual Medicine), Giancarlo Bisagni, Laura Biganzoli(Hospital of Prato), Francesco Cognetti(Apple (Israel)), Anna Turletti(Ospedale Martini), Livio Blasi, Lucia Del Mastro(Ospedale Policlinico San Martino), Emanuela Romagnoli(Medica (Italy)), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Andrea Michelotti(University of Pisa), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo)
Cited by 0
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k